Brilacidin

Enzyme inhibitor

This membrane-lyzing defensin mimetic (FW = 932.98 g/mol; CAS 1224095-98-0; IUPAC: N,N’-bis[3-{[5-(carbamimidoylamino)pentanoyl] amino}-2-[(3R)-pyrrolidin-3-yloxy]-5-(trifluoromethyl)phenyl]pyrimidine- 4,6-dicarboxamide)) is bactericidal (not simply bacteriostatic like most antibiotic) toward a broad spectrum of bacteria, but not mammalian cells. Brilacidin kills many Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecium as well as Gramnegative bacteria, including Eschericia coli and Klebsiella pneumonia (NDM). This action of this drug commend it for use in controlling Acute Bacterial Skin and Skin Structure Infections (ABSSSI). A five-day treatment course is usually effective in the treatment of many infections, and, given its direct membrane-disrupting action, bacteria are highly unlikely to acquire resistance to brilacidin.